Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905536 | 0.84 | FGFR2 (0.47) | METFGFR2FGFR3MAPK1AURKB | |
| SCHEMBL28294470 | 0.82 | PDGFRB (0.47) | METKCNH2 | |
| SCHEMBL20391249 | 0.81 | MET (0.48) | METFGFR2FGFR3KDRFGFR1 | |
| SCHEMBL14793376 | 0.80 | PDGFRB (0.62) | METFGFR2FGFR3KDRFGFR1 | |
| SCHEMBL14916555 | 0.79 | MET (0.41) | METFGFR2FGFR3KDRFGFR1 | |
| SCHEMBL29151078 | 0.78 | MET (0.44) | METFGFR2FGFR3KDRFGFR1 | |
| SCHEMBL22075043 | 0.77 | MET (0.38) | METFGFR2FGFR3MAPK1AURKB | |
| SCHEMBL30745158 | 0.75 | FGFR3 (0.53) | METFGFR2FGFR3MAPK1AURKB | |
| SCHEMBL12470769 | 0.75 | HTR3A (0.53) | MET | |
| SCHEMBL20392608 | 0.75 | CA1 (0.48) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107312009-B | Quinoline compound, preparation method, intermediate, pharmaceutical composition and application thereof | 上海医药集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008144767-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144767-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250799-A1 | Triazolopyridine Compounds | FLT3, RET, MET | MET 3/4885FGFR2 111/4885FGFR3 131/4885 |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K13 | MET 721/4885FGFR2 1363/4885FGFR3 1494/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | MET 1052/4885FGFR2 1955/4885FGFR3 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.